跳至主要内容
临床试验/NCT01711502
NCT01711502已完成不适用

Epidemiology and Therapeutic Management of Metastatic Breast Cancer in Romania: A Retrospective Cohort Study

AstraZeneca15 个研究点 分布在 1 个国家目标入组 128 人开始时间: 2013年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
128
试验地点
15
主要终点
The incidence rate of progression of disease in a cohort of patients newly diagnosed with MBC, either De Novo or having progressed from a non-metastatic stage

研究概览

简要总结

This is a multicenter, national, retrospective chart-review study that will be based on the collection of data from electronical or paper-based medical records with available data on female patients diagnosed with metastatic brest cancer . The main purpose of this study is to provide accurate, evidence based description on the incidence of progression of metastatic breast cancer and its clinical management.

详细描述

Epidemiology and Therapeutic Management of Metastatic Breast Cancer in Romania: A retrospective cohort study

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Female aged 18 years and over Diagnosis of breast cancer according to ICD-10 diagnostic criteria with confirmed metastasis
  • Confirmed diagnosis between 1st July 2010 - 30th June 2011
  • Female patient managed for her disease at the same setting where final diagnosis of MBC was performed

排除标准

  • History of concurrent or other primary malignancies (except curatively resected non-melanoma skin cancer or in situ cervical cancer)

结局指标

主要结局

The incidence rate of progression of disease in a cohort of patients newly diagnosed with MBC, either De Novo or having progressed from a non-metastatic stage

时间窗: At 12 and 18 months after diagnosis

次要结局

  • The progression free survival (PFS) rates(At 12 and 18 months after diagnosis)
  • The progression free survival (PFS) time(At 18 months after diagnosis)
  • Time to progression (TTP)(At 18 months after diagnosis)
  • The clinical and pathological characteristics of newly diagnosed MBC patients(At 18 months after diagnosis)
  • The socio-demographic and anthropometric characteristics of newly diagnosed MBC patients(At 18 months after diagnosis)
  • Health care utilization associated with the disease in Romania(At 18 months after diagnosis)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (15)

Loading locations...

相似试验